International Conferences

Recommended Conferences for Sustained Release

Sustained Release

---

As per available reports about 15 Relevant Journals, 32 Conferences, 10 Workshops are presently dedicated exclusively to Sustained Release Systems and about 21 Open Access articles are being published on sustained release.

Sustained release dosage forms are designed to release a drug at a predetermined rate in order to maintain a constant drug concentration for a specific period of time with minimum side effects. This can be achieved through a variety of formulations, including liposomes and drug-polymer conjugates (an example being hydrogels). Sustained release's definition is more akin to a "controlled release" rather than "sustained". Carriers are also used in designs to increase the effectiveness of drug delivery to the target sites of pharmacological actions. Drug Carriers can be widely used in Drug Delivery systems like Vaccine Drug Delivery, Oral Drug Delivery, Ocular Drug Delivery, BBB Drug Delivery Systems, and also in Nanosystems like Nanosomes, Micro emulsions, Liposomes.

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance:

Their rapid Development arises from the ability to overcome the drawbacks of the currently employed therapeutic drugs, which exhibit poor biopharmaceutical and pharmacokinetic properties. Nanoparticle drug carriers provide alternative formulation strategies for those molecules thus enhancing the scope for commercialization. They are potential for prolonged drug release. The conference too offers growth to expand reserves of knowledge and explore newer realms.

A drug delivery system (DDS) is defined as a formulation or a device that enables the introduction of a therapeutic substance in the body and improves its efficacy and safety by controlling the rate, time, and place of release of drugs in the body. This process includes the administration of the therapeutic product, the release of the active ingredients by the product, and the subsequent transport of the active ingredients across the biological membranes to the site of action. The term therapeutic substance also applies to an agent such as gene therapy that will induce in vivo production of the active therapeutic agent. Drug delivery system is an interface between the patient and the drug. It may be a formulation of the drug to administer it for a therapeutic purpose or a device used to deliver the drug. This distinction between the drug and the device is important, as it is the criterion for regulatory control of the delivery system by the drug or medicine control agency. If a device is introduced into the human body for purposes other than drug administration, such as therapeutic effect by a physical modality or a drug may be incorporated into the device for preventing complications resulting from the device, it is regulated strictly as a device. There is a wide spectrum between drugs and devices, and the allocation to one or the other category is decided on a case by case basis. Sustained release (SR) preparations are not new but several new modifications are being introduced. They are also referred to as “long acting” or “delayed release” when compared to “rapid” or “conventional” release preparations. The term sometimes overlaps with “controlled release,” which implies more sophisticated control of release and not just confined to the time dimension.

The following are the rationale of developing SR

• To extend the duration of action of the drug
• To reduce the frequency of dosing
• To minimize the fluctuations in plasma level
• Improved drug utilization
• Less adverse effects

Advantages of sustained release dosage forms      

• The frequency of drug administration is reduced.           
• Patient compliance can be improved.      
• Drug administration can be made more convenient as well.       
• The blood level oscillation characteristic of multiple dosing of conventional dosage forms is reduced.
• Better control of drug absorption can be attained, since the high blood level peaks that may be observed after administration of a dose of a high availability drug can be reduced.
• The characteristic blood level variations due to multiple dosing of conventional dosage forms can be reduced.

The total amount of drug administered can be reduced, thus:

• Maximizing availability with minimum dose;      
• Minimize or eliminate local side effects; 
• Minimize or eliminate systemic side effects;       
• Minimize drug accumulation with chronic dosing.          
• Safety margins of high potency drugs can be increased and the incidence of both local and systemic adverse side effects can be reduced in sensitive patients.        
• Improve efficiency in treatment. 
• Cure or control condition more promptly
• Improve control of condition       
• Improve bioavailability of some drugs    
• Make use of special effects; e.g. sustain release aspirin for morning relief of arthritis by dosing before bed-time.     
• Economy.

Disadvantages of sustained release dosage forms 

• Probability of dose dumping.      
• Reduced potential for dose adjustment.  
• Cost of single unit higher than conventional dosage forms.        
• Increase potential for first pass metabolism.        
• Requirement for additional patient education for proper medication.    
• Decreased systemic availability in comparison to immediate release conventional dosage forms.         
• Poor invitro and invivo correlations.

Market Analysis:

The global market for ophthalmic devices, diagnostics, and surgical equipment was valued at nearly $16.9 billion in 2012, up from $16.2 billion in 2011.  The market is expected to reach $20.2 billion in 2017, an increase of nearly $3.4 billion during the forecast period and a compound annual growth rate (CAGR) of 3.7% from 2012 to 2017.
 

International Symposium and Workshops

• Cancer Drug Discovery & Preclinical Development Summit London, UK
• 9^th Annual Fragment-Based Drug Discovery
• “3-Dimensional Cell Cultures and Drug Discovery” Workshop organized by IT-LIVER, University of Vienna, Universitätsring
• 4^th International Conference on Recent Advances in Health Sciences Kuala Lumpur, Malaysia
• Workshop on Improving Oral Bioavailability by Lipid-Based Delivery
• 17^th International Pharmaceutical Technology Symposium
• IISC workshop on nanocarriers: An emerging platform for drug delivery
• Discovery on Target Boston, USA
• Re-Entering Antibacterial Drug Development Summit Boston, USA
• Orphan Drugs, Collaborations and Market Access Congress San Diego, USA
• XXIII International Symposium on Medicinal Chemistry Lisboa Congress Center, Praçadas Industrias, Lisbon

List of Best International Conferences:

1. 8^th Pharmaceutics and Novel Drug Delivery Systems Conference 
   March 07-09, 2016 Madrid, Spain
2. 9^th World Drug Delivery Summit June 30-July 02, 2016 New Orleans, USA
3. Industrial Pharmacy Conference April 28-29, 2016 Dubai, UAE
4. 2^nd Pharmacology and Ethnopharmacology Conference 
   May 02-04, 2016 Chicago, USA
5. 4^th European Pharma Congress June 13-15, 2016 Berlin, Germany
6. 7^th Annual Global Pharma Summit June 20-22, 2016 New Orleans, USA
7. 6^th Asia-Pacific Pharma Congress July 14-16, 2016 Kuala Lumpur, Malaysia
8. Nanomedicine Conference July 25-27, 2016 Bangkok, Thailand
9. 3^rd Pharmacology Congress August 08-10, 2016 Birmingham, UK
10. 2^nd Clinical Trials Conference August 22-24, 2016 Philadelphia, USA
11. 4^th Neuropharmacology Conference September 15-17, 2016 San Antonio, USA
12. 7^th Pharmacovigilance and Clinical Trials Conference 
    September 19-21, 2016 Vienna, Austria
13. 5^th Toxicology and Applied Pharmacology Conference 
    September 19-21, 2016 Las Vegas, USA
14. 2^nd Pharma Middle East Congress October 12-14, 2016 Dubai, UAE
15. Marine Drugs and Natural Products Conference 
    July 28-30, 2016 Brisbane, Australia
16. 2^nd Parenterals and Injectables Conference October 24-26, 2016 Istanbul, Turkey
17. Drug Delivery Partnerships 2016 (DDP 2016) January 20-22, 2016 Florida, USA
18. Pharmapack Europe February 10-11, 2016, Paris Expo Porte De Versailles
19. 7^th Annual Global Drug Delivery & Formulation Summit 
    May 23-25, 2016 Berlin, Germany
20. Peptide Drug Design & Delivery Summit 
    February 24-25, 2016 San Francisco, CA
21. 6^th American Drug Delivery & Formulation Summit 
    June 12-14, 2016 Hilton San Diego Resort & Spa
22. Respiratory Drug Delivery (RDD 2016) April 17-21, 2016 Phoenix, Arizona

Relevant Society and Associations:

• Controlled Release Society
• Inhalation Drug Delivery Association
• International society of drug delivery sciences and technology
• American Association of Pharmaceutical Scientists
• Japanese Society of Drug Delivery Systems
• Parenteral Drug Association
• International Association for Pharmaceutical Technology
• International Neuromodulation Society
• Society for Neuroscience
• American Society for Clinical Pharmacology and Therapeutics

Companies:

• AstraZeneca
• Accredo Therapeutics
• Actelion Pharmaceuticals US, Inc
• Bayer HealthCare
• CRITICAL CARE
• Cané Medical Technology
• CVS Caremark
• CuraScript
• Fairview Specialty Pharmacy
• Gilead Sciences
• Vivisol
• AIM
• Henry Schein
• Snap Diagnostics
• MediLexicon
• Nicos Group Inc.
• Bausch & Lomb Instruments
• JEDMED
• Miami Medical
• Image Stream Medical

This page will be updated regularly.

This page was last updated on April 27, 2024